ROCKLAND, Mass.--(BUSINESS WIRE)--June 13, 2006--BioSphere Medical, Inc. (NASDAQ: BSMD - News), a medical device company that pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization, today announced its participation in a Phase II, single-arm clinical study to treat patients with primary liver cancer.
